Oncology

A groundbreaking clinical trial in Lethbridge is utilizing MRI-guided adaptive therapy to condense weeks of prostate cancer radiation into just two treatments.

GT Biopharma secures FDA clearance for a Phase 1 trial of GTB-5550 in multiple myeloma, a strategic pivot for its TriKE® platform, but the trial's start hinges on securing grant funding.

Axe Compute sells its Helomics cancer lab, completing its pivot to a pure-play AI infrastructure provider and betting its future on the GPU gold rush.

Imvax has promising data and a clear regulatory path for its glioblastoma therapy. Now it faces the ultimate test: raising millions to fund the final push.

FDA Fast Track for Kestrel's KST-6051 signals more than just a new drug; it reveals a new strategy in the war on cancer, backed by Big Pharma's billions.

Promising trial data for a novel drug targets a stubborn lung cancer mutation, signaling a major strategic advance for BlossomHill Therapeutics and the oncology field.

TOLREMO's successful Phase I trial for TT125-802 validates a novel strategy against NSCLC, offering new hope by targeting cancer's clever escape routes.

The Euronext-listed firm is moving beyond equipment sales, creating a recurring revenue engine in Brazil's $9B oncology diagnostics market via a novel partnership.

Singaporean scientists are reprogramming immune cells with magnetic fields, eradicating tumors in preclinical trials and offering hope for a future without chemo.

Third Arc Bio's move to fund clinical development for a new cancer drug validates Adagene's SAFEbody platform, de-risking its finances and setting the stage.

Starton Therapeutics heads to a key investor conference not with a new molecule, but a new method. Can their delivery tech turn old drugs into new blockbusters?

The oncology firm's revenue dips and losses widen, but a strategic shift to hospitals and key regulatory wins may pave the way for long-term growth.

With a key investor conference ahead, MacroGenics balances promising cancer drug data against a history of clinical setbacks and a major strategic pivot.

Dr. Timothy Donahue's new leadership at Weill Cornell while on Trethera's board highlights a key trend: integrating top clinical minds to accelerate drug development.

As Aktis Oncology presents at key investor conferences, it showcases a precision miniprotein platform and a major Eli Lilly deal in a booming market.

Takeda's new rare blood cancer drug, MIMRYLO, partners with Onco360 in a strategic 'ultra-narrow' launch, signaling a major shift in patient care.

Remix Therapeutics' hire of Nicole Sweeny is more than a new exec; it's a strategic bet on its RNA platform and a sign of the industry's maturation.

A high schooler's award-winning AI model to simulate cancer cells is more than a project; it's a blueprint for a faster, cheaper, and more humane future.

Alterome Therapeutics brings on a heavy-hitting CFO in Johanna Mylet, who guided Poseida to an IPO and Roche acquisition. What does this signal for its future?

With a new cancer drug showing promise but cash reserves dwindling, Citius Pharma's CEO faces a critical test: convincing investors the pipeline is worth the risk.